AstraZeneca had a disappointing trial readout with its AKT inhibitor Truqap in breast cancer in June, so unsurprisingly it is trumpeting a first-in-class win for the drug in prostate cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,